L.S. EFREMOVA, L.V. VASILIEVA

 Voronezh State Medical University named after N.N. Burdenko, Voronezh

 Contact details:

Efremova L.S. — post-graduate student of the Department of Propaedeutics of Internal Diseases

Address: 10 Studentcheskaya St., Voronezh, Russian Federation, 394036, tel.: +7-903-858-22-00, e-mail: ljudmilarogowa@yandex.ru

 The relevance of the problem of the combined course of chronic heart failure (CHF) and diabetes mellitus (DM) is due to the high prevalence of this comorbid pathology, the frequent development of complications and adverse prognosis. Pathophysiological mechanisms of CHF and DM development include a number of pathological processes: neurohumoral activation, endothelial dysfunction, oxidative stress, chronic inflammation, structural and functional disturbance of the extracellular matrix, damaging effect of hyperglycemia, and atherogenesis. Biomarkers are involved in the development of these processes, and determination of their content in the blood serum of patients contributes to the early diagnosis of CHF progression in patients with diabetes and the development of complications such as myocardial infarction, stroke, and sudden cardiac death. This review systematizes recent literature data on the main mechanisms of CHF and DM development and the role of biomarkers in these mechanisms — aldosterone, tissue inhibitor of matrix metalloproteinases-1, tumor necrosis factor-alpha, vascular endothelial growth factor, fibroblast growth factors, and lipoprotein-associated phospholipase-2, which can be used for early diagnosis of adverse cardiovascular events in patients with CHF and DM.

Key words: chronic heart failure, diabetes mellitus, pathogenesis, biomarkers.

REFERENCES

1. Chronic heart failure. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal, 2020, vol. 25, no. 11, pp. 40–83 (in Russ.). DOI: 10.15829/1560-4071-2020-4083
2. Mareev V.Yu., Fomin I.V., Ageev F. T. et al. Clinical guidelines OSSN-RKO-RNMOT. Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiya, 2018, vol. 58, no. 6S, pp. 8–158 (in Russ.). DOI: 10.18087/cardio.2475
3. Mardanov B.U., Korneeva M.N., Akhmedova E. B. Heart failure and diabetes mellitus: some issues of etiopathogenesis, prognosis and treatment. Ratsional’naya farmakoterapiya v kardiologii, 2016, vol. 12, no. 6, pp. 743–748 (in Russ.). DOI: 10.20996/1819-6446-2016-126-743-748
4. Mamedov M.N., Bondarenko I.Z., Mareev Yu.V., Kanorskiy C.G., Khalimov Yu.Sh., Agafonov P.V. New position on chronic heart failure of the Association for Heart Failure of the European Society of Cardiology in Patients with Diabetes Mellitus: comments by Russian experts. Mezhdunarodnyy zhurnal serdtsa i sosudistykh zabolevaniy, 2018, no. 20, pp. 43–50 (in Russ.). DOI: 10.24412/2311-1623-2018-20-43-50
5. Seferovic P.M., Petrie M.C., Filippatos G.S. et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2018, vol. 20 (5), pp. 853–872. DOI: 1011002/ejhf11170
6. Obrezan A.G., Kulikov N.V. Neurohumoral imbalance in chronic heart failure: classical and modern positions. Rossiyskiy kardiologicheskiy zhurnal, 2017, vol. 9, no. 149, pp. 83–92 (in Russ.). DOI: 10.15829/1560-4071-2017-9-83-92
7. Shevelek A.N. Influence of therapy with blockers of the renin-angiotensin system on the level of blood aldosterone in patients with chronic heart failure with preserved left ventricular ejection fraction. Meditsinskiy vestnik Yuga Rossii, 2020, vol. 11, no. 4, pp. 67–73 (in Russ.). DOI: 10.21886/2219-8075-2020-11-4-67-73
8. Pugliese N.R., Masi S., Taddei, S. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail. Rev, 2020, vol. 25, pp. 31–42. DOI: 10.1007/s10741-019-09855-5
9. Gosteva E.V., Vasil’eva L.V., Osipova O.A., Starodubtseva I.A., Suslova E.Yu. Dynamic assessment of the effect of pharmacotherapy on the structural and functional parameters of the heart in patients with chronic heart failure with intermediate ejection fraction, taking into account comorbid pathology. Terapiya, 2021, vol. 1, no. 43, pp. 39–46 (in Russ.). DOI: 10.18565/therapy.2021.1.39-46
10. Kashtalap V.V., Sedykh D.Yu., Barbarash O.L. Mineralocorticoid receptor antagonists in the treatment of patients with postinfarction heart failure: the role of eplerenone. Consilium Medicum, 2019, vol. 21, no. 1, pp. 51–55 (in Russ.). DOI: 10.26442/20751753.2019.1.190260
11. Myasoedova E.I. The content of matrix metalloproteinase-1 and its inhibitor in patients with ischemic cardiomyopathy. Vestnik novykh meditsinskikh tekhnologiy, 2016, vol. 23, no. 4, pp. 50–53 (in Russ.). DOI: 10.12737/23850
12. Toba H., Lindsey M.L. Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly. Pharmacol. Ther, 2019, vol. 193, pp. 99–120. DOI: 10.1016/j.pharmthera.2018.08.014
13. Pecherina T.B., Barbarash O.L. Matrix metalloproteinases. clinical and prognostic significance in patients with myocardial infarction. Fundamental’naya i klinicheskaya meditsina, 2019, vol. 4, no. 2, pp. 84–94 (in Russ.). DOI: 10.23946/2500-0764-2019-4-2-84-94
14. El-Din D.S., Amin A.I., Egiza A.O. Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes. Open Access Macedonian J of Med Sciences, 2018, vol. 6 (2), pp. 314–319.
15. Lebedev D. A., Lyasnikova E. A., Vasil’eva A. A., Vasil’eva E. Yu., Babenko A. Yu., Shlyakhto E. V. Molecular biomarker profile of chronic heart failure with intermediate and preserved left ejection fraction ventricle against the background of type 2 diabetes mellitus. Rossiyskiy kardiologicheskiy zhurnal, 2020, vol. 25, no. 10, pp. 39–67 (in Russ.). DOI: 10.15829/1560-4071-2020-3967
16. Markelova E.V., Zdor V.V., Romanchuk A.L., Birko O.N. Matrix metalloproteinases: their relationship with the cytokine system, diagnostic and prognostic potential. Immunopatologiya, allergologiya, infektologiya, 2016, no. 2, pp. 11–22 (in Russ.). DOI: 10.14427/jipai.2016.2.23
17. Efremova L.S., Vasil’eva L.V., Gosteva E.V. The value of a tissue inhibitor of matrix metalloproteinases-1 and tumor necrosis factor alpha for the diagnosis of progression of chronic heart failure in patients with diabetes mellitus. Meditsinskiy al’manakh, 2021, vol. 4, no. 69, pp. 48–54 (in Russ.).
18. Khazova E.V., Bulashova O.V., Oslopov V.N., Malkova M.I. et al. Tumor necrosis factor a — a marker of systemic inflammation in patients with heart failure. Prakticheskaya meditsina, 2017, vol. 2, no. 103, pp. 24–27 (in Russ.).
19. Schumacher S.M., Naga Prasad S.V. Tumor Necrosis Factor-a in Heart Failure: An updated review. Curr Cardiol Rep, 2018, vol. 20 (11), p. 117. DOI: 10.1007/s11886-018-1067-7
20. Akash M.S.H., Rehman K., Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J. Cell. Biochem, 2018, vol. 119 (1), pp. 105–110. DOI: 10.1002/jcb.26174
21. Topolyanskaya S.V. Tumor necrosis factor-alpha and age-associated pathology. Arkhiv» vnutrenney meditsiny, 2020, vol. 10, no. 6, pp. 414–421 (in Russ.). DOI: 10.20514/2226-6704-2020-10-6-414-421
22. Shamitova E.N., Symulova I.S., Levanova M.M., Kashevarova E.A. Mechanisms and factors of angiogenesis. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy, 2019, no. 9, pp. 30–34 (in Russ.), available: https://appliedresearch.ru/ru/article/view?id=12846 (accessed on: 10.03.2022)
23. Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M., Mihu C., Istrate M., Moldova I.M., Roman A.L., Mihu C.M. Vascular endothelial growth factor (VEGF) — key factor in normal and pathological angiogenesis. Rom J Morphol Embryol, 2018, vol. 59 (2), pp. 455–467. PMID: 30173249.
24. Shevchenko Yu.L., Borshchev G.G. Stimulation of angiogenesis by endogenous growth factors. Vestnik Natsional’nogo mediko-khirurgicheskogo Tsentra im. N.I. Pirogova, 2018, vol. 13, no. 3, pp. 96–102 (in Russ.). DOI: 10.25881/BPNMSC.2018.73.55.022
25. Teplyakov A.T., Berezikova E.N., Shilov S.N., Grakova E.V., Torim Yu.Yu., Efremov A.V., Safronov I.D., Pustovetova M.G., Popova A.A., Andriyanova A.V. Pathogenetic and prognostic significance of growth factors in the development of chronic heart failure. Kardiologiya, 2017, vol. 57, no. 10, pp. 20–28 (in Russ.). DOI: 10.18087/cardio.2017.10.10039
26. Kuznik B.I., Khavinson V.Kh., Lin’kova N.S., Ryzhak G.A., Sall’ T.S., Trofimova S.V. Fibroblast growth factors FGF19, FGF21, FGF23 as endocrine regulators of physiological functions and geroprotectors. Epigenetic mechanisms of regulation. Uspekhi sovremennoy biologii, 2017, vol. 137, no. 1, pp. 84–99 (in Russ.).
27. Phan P., Saikia B.B., Sonnaila S., Agrawal S., Alraawi Z., Kumar T.K.S, Iyer S. The Saga of Endocrine FGFs. Cells, 2021, Sep. 14, vol. 10 (9), p. 2418. doi: 10.3390/cells10092418
28. Zhang X., Yang L., Xu X., Tang F., Yi P., Qiu B., Hao Y. A review of fibroblast growth factor 21 in diabetic cardiomyopathy. Heart Fail Rev, 2019, vol. 24 (6), pp. 1005–1017. doi: 10.1007/s10741-019-09809-x
29. Proshchay G.A., Vorokhobina N.V., Zagarskikh E.Yu., Partsernyak S.A., Partsernyak A.S. Fibroblast growth factor 21 and its influence on metabolic processes in the human body. Vestnik Sankt-Peterburgskogo universiteta. Meditsina, 2018, vol. 13, no. 1, pp. 38–45 (in Russ.). DOI: 10.21638/11701/spbu11.2018.104
30. Osmankulova G.E., Noruzbaeva A.M. Lipoprotein-associated phospholipase A2 in patients with coronary heart disease and metabolic syndrome. Kardiologicheskiy vestnik, 2016, vol. 11, no. 1, pp. 34–37 (in Russ.). DOI: 10.18565/cardio.2016.1.49-50
31. Huang F., Wang K., Shen J. Lipoprotein‐associated phospholipase A2: The story continues. Medicinal Research Reviews, 2020, vol. 40 (1), pp.79–134. DOI: 10.1002/med.21597
32. Benderly M., Sapir B., Kalter-Leibovici O., Zimlichman R. Lipoprotein associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers, 2017, vol. 22 (3–4), pp. 219–224. DOI: 10.3109/1354750X.2016.1171910
33. Svarovskaya A.V., Teplyakov A.T., Gusakova A.M., Garganeeva A.A. The role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome who underwent coronary stenting. Kardiologiya, 2020, vol. 60, no. 8, pp. 98–105 (in Russ.). DOI: 10.18087/cardio.2020.8.n966
34. Dushina A.G., Lopina E.A., Libis R.A. Features of chronic heart failure depending on the ejection fraction of the left ventricle. Rossiyskiy kardiologicheskiy zhurnal, 2019, vol. 24, no. 2, pp. 7–11 (in Russ.). DOI: 10.15829/1560-4071-2019-2-7-11
35. Drapkina O.M., Dzhioeva O.N. Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction. Kardiovaskulyarnaya terapiya i profilaktika, 2020, vol. 19, no. 2, pp. 24–54 (in Russ.). DOI: 10.15829/1728-8800-2020-2454